1-乙基-3-甲基-吡唑-4-甲醛 | 676348-38-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-乙基-3-甲基-吡唑-4-甲醛
• 中文别名: 1-乙基-3-甲基吡唑-4-甲醛
• 英文名称: 1-ethyl-3-methyl-1H-pyrazole-4-carbaldehyde
• 英文别名: 1-ethyl-3-methylpyrazole-4-carbaldehyde
• CAS: 676348-38-2
• 化学式: C₇H₁₀N₂O
• mdl: MFCD02056541
• 分子量: 138.169
• InChiKey: KHIVHAYYUUFWPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933199090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Ethyl-3-methyl-1h-pyrazole-4-carbaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Ethyl-3-methyl-1h-pyrazole-4-carbaldehyde
CAS number: 676348-38-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H10N2O
Molecular weight: 138.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-乙基-3-甲基-吡唑-4-甲醛 在 N,N-二甲基甲酰胺 sodium chlorite 、 sodium dihydrogenphosphate 、 2-甲基-2-丁烯 、 草酰氯 、 偶氮二甲酸二异丙酯 、 四丁基氟化铵 、 二甲基亚砜 、 N,N-二异丙基乙胺 、 间氯过氧苯甲酸 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 氯仿 、 水 、 丙酮 为溶剂， 反应 90.58h， 生成 (-)-N-(5-cyanopyridin-2-yl)-2-[(1-ethyl-3-methyl-1H-pyrazol-4-yl)oxymethyl]-2-phenylcyclopropanecarboxamide
  参考文献：
  名称：

  CYCLOPROPANE DERIVATIVES

  摘要：

  由以下公式（I）表示的环丙烷衍生物或其药用可接受的盐具有促进促进醒脑肽受体的作用，因此，极其有用作为预防或治疗由促进醒脑肽引起的睡眠障碍或失眠症的药物，包括失眠作为典型例子：其中A1、A2和A3各自独立地表示芳基、杂环烷基或类似物，R1、R2和R3各自独立地表示氢原子、C1-6烷基或类似物，X表示氧原子或类似物，L表示键或类似物。

  公开号：

  US20120165339A1
• 作为产物：
  描述：

  1-ethyl-2-(propan-2-ylidene)hydrazine 、 N,N-二甲基甲酰胺 在 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以67%的产率得到1-乙基-3-甲基-吡唑-4-甲醛
  参考文献：
  名称：

  Modulators of STING (Stimulator of Interferon Genes)

  摘要：

  通式（I）的化合物： 或其药用可接受盐，制备这些化合物的方法，含有这些化合物的组合物，以及这些化合物的用途。

  公开号：

  US20210087180A1

文献信息

• Substituted Spiro-amide Compounds
  申请人：Schunk Stefan

  公开号：US20100249095A1

  公开（公告）日：2010-09-30

  Substituted spiro-amide compounds corresponding to formula I in which R5 through R8, D, X, Y and Z have defined meanings, processes for preparing such spiro-amide compounds, pharmaceutical compositions containing such compounds, and methods of using such spiro-amide compounds for treating and/or inhibiting disorders or disease states mediated at least in part by the bradykinin 1 receptor.

  将与式I相对应的螺环酰胺化合物替代为R5至R8、D、X、Y和Z具有定义含义的过程，用于制备这种螺环酰胺化合物，含有这种化合物的药物组合物，以及使用这种螺环酰胺化合物治疗和/或抑制至少部分由激肽酶1受体介导的疾病或疾病状态的方法。
• FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF
  申请人：Sakai Nozomu

  公开号：US20090137595A1

  公开（公告）日：2009-05-28

  The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.

  本发明提供了一种具有强大激酶抑制活性的融合杂环衍生物及其用途。 一种由以下式（I）表示的化合物： 其中除了特定化合物或其盐外，每个符号如规范中定义，以及含有该化合物或其前药的药用剂，该化合物是激酶（VEGFR、VEGFR2、PDGFR、Raf）抑制剂，血管生成抑制剂，用于癌症的预防或治疗的药剂，癌症生长抑制剂或癌症转移抑制剂。
• Adducts of Triallylborane with Ammonia and Aliphatic Amines as Stoichiometric Allylating Agents for Aminoallylation Reaction of Carbonyl Compounds
  作者：Nikolai Yu. Kuznetsov、Rabdan M. Tikhov、Tatiana V. Strelkova、Yuri N. Bubnov

  DOI：10.1021/acs.orglett.8b01317

  日期：2018.6.15

  Triallylborane–amines adducts are effective stoichiometric allylating agents in the aminoallylation reaction of carbonyl compounds in methanol. Moreover, copper-catalyzed diastereoselective allylation of Ellman’s imine was achieved with triallylborane–methylamine adduct.

  三烯丙基硼烷-胺加合物在甲醇中羰基化合物的氨基烯丙基化反应中是有效的化学计量烯丙基化剂。此外，用三烯丙基硼烷-甲胺加合物实现了铜催化的埃尔曼亚胺的非对映选择性烯丙基化。
• [EN] NEW PYRIDIN-2-ONE COMPOUNDS USEFUL AS INHIBITORS OF THROMBIN<br/>[FR] NOUVEAUX COMPOSES DE PYRIDIN-2-ONE UTILISABLES EN TANT QU'INHIBITEURS DE THROMBINE
  申请人：ASTRAZENECA AB

  公开号：WO2005075424A1

  公开（公告）日：2005-08-18

  There is provided a compound of formula I, wherein the dashed line, R1, R2, R3a, R3b, A, D, E, G and L have meanings given in the description, which compounds are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is beneficial (e.g. conditions, such as thrombo-embolisms, where inhibition of thrombin is required or desired, and/or conditions where anticoagulant therapy is indicated).

  提供了一个式I的化合物，其中虚线、R1、R2、R3a、R3b、A、D、E、G和L的含义如描述中所示，这些化合物可用作竞争性蛋白酶抑制剂，如凝血酶，或者可用作其前药，特别适用于需要抑制凝血酶有益的情况的治疗（例如需要或希望抑制凝血酶的情况，如血栓栓塞等情况，以及需要抗凝治疗的情况）。
• SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS
  申请人：Genosco

  公开号：US20150111883A1

  公开（公告）日：2015-04-23

  Compounds of Formula (I) and methods for inhibiting kinases, including spleen tyrosine kinases, are disclosed. Also disclosed are methods for treating a kinase-mediated disease or condition by administering to a subject a therapeutically effective amount of the compound of Formula (I).

  公式（I）的化合物和抑制激酶的方法被披露。还披露了通过向受试者投予公式（I）的化合物的治疗有效量来治疗激酶介导的疾病或病况的方法。